NCT00960362 - An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

InflammationSystemic Lupus Erythematosus (SLE)

Interventions

DRUG

AGS-009

Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)

DRUG

placebo

Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.

Trial Locations (6)

Lake Success

Duncansville

Durham

Birmingham

Kansas City

Dallas